5:40 PM
 | 
Jun 13, 2014
 |  BC Extra  |  Company News

Nektar up on FDA panel decision for OIC

Nektar Therapeutics (NASDAQ:NKTR) jumped $1.35 (11%) to $13.89 on Friday after the majority of panelists on FDA's Anesthetic and Analgesic Drug Products Advisory Committee said on Thursday that cardiovascular outcomes trials weren't warranted for peripheral mu opioid receptor ( OPRM1; MOR) antagonists to treat opioid-induced constipation (OIC) in patients with chronic non-cancer pain. Nektar's Movantik naloxegol, a pegylated form of the peripheral MOR antagonist...

Read the full 320 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >